SAILIFE

- Sai Life Sciences has provided the audio recording link for its Earnings Conference Call held on November 06, 2026. - The call covered Un-audited Financial Results for Q2 and H1 ended September 30, 2026. - The recording is accessible via the provided link and on the company's website.

- Q2 FY27 Revenue grew 23% YoY to ₹659 Cr; PAT rose 17% YoY to ₹98 Cr. - EBITDA increased 20% YoY to ₹187 Cr with a 28% EBITDA margin. - H1 FY27 capex stood at ₹621 Cr. - Management expects stronger H2 FY27 performance driven by pipeline progression and capacity ramp-up.

Q2 FY27 Consolidated Revenue ₹659Cr vs ₹537Cr (▲23% YoY) EBITDA ₹187Cr vs ₹156Cr (▲20% YoY) PAT ₹98Cr vs ₹84Cr (▲17% YoY) EBITDA Margin 28% vs 29% (▼100bps)

Q2 FY27 Standalone Revenue ₹647.1Cr vs ₹526.7Cr (▲23% YoY) EBITDA ₹178.2Cr vs ₹139.8Cr (▲27% YoY) PAT ₹96.0Cr vs ₹82.9Cr (▲16% YoY) EBITDA Margin 27.5% vs 26.6% (▲99bps)

- Board approved appointment of three Senior Management Personnel effective November 5, 2026: Sidhartha Das (Head - HR), Vijay Kumar Suthari (Head - Quality & Regulatory), and Sriram Gopalakrishnan (Head - Corporate Communications). - Approved Q2 FY27 financial results and allotted 1,08,005 equity shares under ESOP schemes.

Q2 FY27 Consolidated Revenue ₹658.59Cr vs ₹537.47Cr (▲22.5% YoY) EBITDA ₹186.39Cr vs ₹145.83Cr (▲27.8% YoY) PAT ₹98.32Cr vs ₹83.84Cr (▲17.3% YoY) EBITDA Margin 28.30% vs 27.13% (▲117bps)